Journal of psychoactive drugs
January 1, 2023
Aviad Hadar, Jonathan David, Nadav Shalit et al.
93 citations
Psychedelics were used to treat psychiatric conditions before their prohibition in the late 1960s. Over the past three decades, research interest in their therapeutic potential has revived, with expected FDA approvals for various conditions. This bibliometric analysis characterized the top-cited 100 articles in the field, which were cited between 82 and 668 times (median 125; mean 158). Fifty-four percent of these articles were published in the last decade (2010-2020). Network and author impact analysis identified key figures and collaboration networks. The UK, USA, Switzerland, Spain, and Brazil lead the field. The findings facilitate research evaluation, data-driven funding policies, and a practical map for researchers and clinicians.
Frontiers in Psychiatry
January 10, 2023
Jonina Rabinowitz, Raz Gross, Shaul Lev‐ran
15 citations
Past use of peyote or mescaline was associated with 32% lower odds of past-year substance dependence or abuse compared with people who had never used classic psychedelics, after controlling for sociodemographic factors, other illicit drug use, and mental health variables. In contrast, past use of LSD or psilocybin was associated with increased odds of substance use disorder, especially with more recent LSD use. No association was found between any classic psychedelic use and nicotine dependence. The authors suggest the difference may stem from pharmacological distinctions or the ceremonial context in which peyote or mescaline are traditionally taken.
bioRxiv Preprint Server
March 28, 2024
Ophir Netzer, Noa Magal, Yonatan Stern et al.
7 citations
preprint
Survivors of the October 7, 2023 Supernova festival attack in Israel who were under the influence of MDMA during the trauma reported feeling less overwhelmed, had more social interactions, better sleep quality, and reduced psychological distress compared to survivors not using any substance. In contrast, those who consumed cannabis or alcohol during the attack reported higher psychological distress, more PTSD symptoms, and worse sleep quality. The findings suggest MDMA's known effects of reducing negative emotions and increasing prosociality may have buffered trauma impact, while cannabis and alcohol had deleterious effects. The study included 772 adult survivors assessed one to four months after the attack.